[The use of endolymphatic chemotherapy in patients with metastatic stomach cancer].
The results of the endolymphatic chemotherapy application in patients with metastatic cancer of stomach are presented. The low toxicity and high effectiveness were suggested. One-year survival was achieved in 42.2% of patients.
Bondar'
G V
GV
Zabudkin
A F
AF
Bukhteev
S V
SV
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality; D018279:Carcinoma, Signet Ring Cell / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007272:Injections, Intralymphatic; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality
D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate
Primenenie éndolimfaticheskoĭ khimioterapii u bol'nykh s metastaticheskim rakom zheludka.